Copyright © 2019. Inderes Oy. All rights reserved.

Orion

Analyst

Petri Kajaani

Petri Kajaani

Analyytikko

Read more

Company annual reports

Latest insider trading

Net impact profile

Stock release
5.3.
2021

ORION CORPORATION MANAGERS’ TRANSACTIONS 5 MARCH 2021 at 11.00 EET             
         

Orion Corporation: Managers’ transactions – Jukka Ylppö

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

____________________________________________

Stock release
3.3.
2021

ORION CORPORATION NOTICE TO ANNUAL GENERAL MEETING/STOCK EXCHANGE RELEASE 3 MARCH 2021 at 11.30 EET             
         

Change to the Notice of Orion Corporation’s Annual General Meeting

Stock release
2.3.
2021

ORION CORPORATION STOCK EXCHANGE RELEASE 2 MARCH 2021 at 11.45 EET             
         

Orion Group Financial Statement documents 2020, Corporate Governance Statement and Remuneration Report published

Stock release
2.3.
2021

ORION CORPORATION MANAGERS’ TRANSACTIONS 2 MARCH 2021 at 9.00 EET             
         

Orion Corporation: Managers’ transactions – Timo Lappalainen

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

____________________________________________

Stock release
2.3.
2021

ORION CORPORATION MANAGERS’ TRANSACTIONS 2 MARCH 2021 at 9.00 EET             
         

Orion Corporation: Managers’ transactions – Virve Laitinen

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

____________________________________________

Stock release
2.3.
2021

ORION CORPORATION MANAGERS’ TRANSACTIONS 2 MARCH 2021 at 9.00 EET             
         

Orion Corporation: Managers’ transactions – Satu Ahomäki

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

____________________________________________

Stock release
2.3.
2021

ORION CORPORATION MANAGERS’ TRANSACTIONS 2 MARCH 2021 at 9.00 EET             
         

Orion Corporation: Managers’ transactions – Olli Huotari

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

____________________________________________

Stock release
2.3.
2021

ORION CORPORATION MANAGERS’ TRANSACTIONS 2 MARCH 2021 at 9.00 EET             
         

Orion Corporation: Managers’ transactions – Liisa Hurme

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

____________________________________________

Stock release
2.3.
2021

ORION CORPORATION MANAGERS’ TRANSACTIONS 2 MARCH 2021 at 9.00 EET             
         

Orion Corporation: Managers’ transactions – Jari Karlson

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

____________________________________________

Stock release
1.3.
2021

ORION CORPORATION STOCK EXCHANGE RELEASE 1 MARCH 2021 at 18.45 EET             
         

Orion Corporation: Transfer of 99,768 own B shares on 1 March 2021

Orion

Orion lyhyesti

Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs.